ATE545023T1 - Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung - Google Patents

Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung

Info

Publication number
ATE545023T1
ATE545023T1 AT08845473T AT08845473T ATE545023T1 AT E545023 T1 ATE545023 T1 AT E545023T1 AT 08845473 T AT08845473 T AT 08845473T AT 08845473 T AT08845473 T AT 08845473T AT E545023 T1 ATE545023 T1 AT E545023T1
Authority
AT
Austria
Prior art keywords
ability
analog compound
zearalenone analog
cancer
subject
Prior art date
Application number
AT08845473T
Other languages
English (en)
Inventor
John Wang
Sergei Agoulnik
Kenichi Nomoto
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE545023T1 publication Critical patent/ATE545023T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AT08845473T 2007-10-29 2008-10-29 Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung ATE545023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79607P 2007-10-29 2007-10-29
PCT/US2008/081646 WO2009058908A2 (en) 2007-10-29 2008-10-29 Methods for prognosing the ability of a zearalenone analog compound to treat cancer

Publications (1)

Publication Number Publication Date
ATE545023T1 true ATE545023T1 (de) 2012-02-15

Family

ID=40265002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08845473T ATE545023T1 (de) 2007-10-29 2008-10-29 Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung

Country Status (7)

Country Link
US (2) US20090170925A1 (de)
EP (2) EP2215471B1 (de)
JP (3) JP5564431B2 (de)
AT (1) ATE545023T1 (de)
AU (1) AU2008318690B2 (de)
CA (1) CA2704048A1 (de)
WO (1) WO2009058908A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008279027B8 (en) 2007-07-25 2014-03-06 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer
KR102486321B1 (ko) * 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
GB201602305D0 (en) * 2016-02-09 2016-03-23 Medical Res Council And Imp Innovations Ltd TB Biomarkers
CN110684754B (zh) * 2019-10-25 2021-11-23 江南大学 一种真菌毒素zen降解酶突变体及其应用
CN110669745B (zh) * 2019-10-25 2021-11-23 江南大学 一种热稳定性提高的玉米赤霉烯酮降解酶突变体及其应用
CN115154460A (zh) * 2022-08-10 2022-10-11 浙江大学 大环类化合物在制备治疗血液瘤药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323845A (en) 1928-10-30 1930-01-16 John Thomas Hay Corrosion resistant ferrous alloy
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
EP0552108B1 (de) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Phasenmodulationsenergieübertragungsfluoroimmunassay
DE69334053T2 (de) 1992-04-10 2007-01-04 Dana-Farber Cancer Institute, Inc., Boston Immunnachweis eines aktivierungszustandsspezifischen phosphoproteins
GB9225396D0 (en) 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds
CA2166871A1 (en) 1993-07-29 1995-02-09 Neill A. Giese Receptor function assays
JPH0840893A (ja) 1993-08-31 1996-02-13 Takeda Chem Ind Ltd インターロイキン−1産生抑制剤
ATE163231T1 (de) 1993-11-23 1998-02-15 Genentech Inc Kinaserezeptoraktivierungstest
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6441140B1 (en) 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
AU779438B2 (en) 1998-12-24 2005-01-27 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
WO2001051928A1 (en) * 2000-01-12 2001-07-19 Ventana Medical Systems, Inc. Method for quantitating a protein by image analysis
JP4317913B2 (ja) * 2000-04-14 2009-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド Aktタンパク質発現の定量方法
AU6513701A (en) 2000-05-30 2001-12-11 Advanced Res & Tech Inst Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
US7071164B2 (en) * 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
EP1427810B9 (de) * 2001-08-21 2012-04-25 Ventana Medical Systems, Inc. Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
WO2003056036A2 (en) * 2001-12-21 2003-07-10 The Wellcome Trust Genes
US20040096855A1 (en) * 2001-12-24 2004-05-20 Michael Stratton Genes
KR101210018B1 (ko) * 2002-03-08 2012-12-07 에자이 알앤드디 매니지먼트 가부시키가이샤 약물로서 유용한 거대고리 화합물
US7915306B2 (en) 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
US6942987B2 (en) 2002-05-15 2005-09-13 Pharmacopeia Drug Discovery, Inc. Methods for measuring kinase activity
UA84156C2 (ru) * 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
JP2007530453A (ja) * 2004-03-19 2007-11-01 ザ ペン ステート リサーチ ファウンデーション 黒色腫を治療するためのコンビナトリアル法および組成物
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
EP1794137A4 (de) * 2004-09-27 2009-12-02 Kosan Biosciences Inc Spezifische kinase-hemmer
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US7812143B2 (en) * 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
AU2008279027B8 (en) * 2007-07-25 2014-03-06 Eisai R & D Management Co., Ltd. Multikinase inhibitors for use in the treatment of cancer

Also Published As

Publication number Publication date
EP2453234B1 (de) 2014-01-15
JP2014042531A (ja) 2014-03-13
JP5564431B2 (ja) 2014-07-30
EP2453234A2 (de) 2012-05-16
EP2453234A3 (de) 2012-08-29
AU2008318690B2 (en) 2015-08-13
US20090170925A1 (en) 2009-07-02
JP2016034287A (ja) 2016-03-17
AU2008318690A1 (en) 2009-05-07
WO2009058908A2 (en) 2009-05-07
EP2215471A2 (de) 2010-08-11
CA2704048A1 (en) 2009-05-07
EP2215471B1 (de) 2012-02-08
WO2009058908A3 (en) 2009-10-22
US20160291027A1 (en) 2016-10-06
JP2011502473A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
ATE545023T1 (de) Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung
ATE523786T1 (de) In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
WO2009049214A3 (en) Inhibition and treatment of prostate cancer metastasis
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
WO2010071846A3 (en) Compounds for treating neuropsychiatric conditions
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
TW200642695A (en) Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
DE602005011656D1 (de) Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
DE602007001241D1 (de) Vorrichtung zur Zuweisung von Unterkanälen und entsprechendes Verfahren
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
DE502005004218D1 (de) Verfahren zur umesterung von fetten und ölen biologischen ursprungs mittels alkoholyse unter verwendung spezieller kohlensäuresalze
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
ATE540676T1 (de) Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2013119950A3 (en) Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
ATE507198T1 (de) Mehrstufiges kontinuierliches verfahren zur hydroformylierung von höheren olefinen oder olefingemischen
EA201791236A1 (ru) Применение ингибиторов пан fgfr и способ идентификации пациентов, заболевших раком, для лечения с помощью ингибитора пан fgfr